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Omiganan, a bactericidal and fungicidal cationic peptide being developed as a topical gel for prevention of
catheter-associated infections, inhibited commonly occurring fungal pathogens including Candida spp. (106
isolates) at <256 g/ml and molds (including 10 Aspergillus isolates) at <1,024 g/ml. All fungi were inhibited
by omiganan at concentrations well below the 1% (10,000 g/ml) clinical formulation, including species with
reduced susceptibility to azoles and echinocandins.
Indwelling venous access devices, especially central venous
catheters, are a primary source of nosocomial bloodstream
infections, accounting for an estimated 250,000 cases annually
in the United States (15). While staphylococci and enterococci
produce most bloodstream infections, data from the National
Nosocomial Infections Surveillance system and other pub-
lished sources has consistently shown that approximately 8 to
10% are produced by Candida spp. (1, 14, 15). Given the
importance of fungi as pathogens in compromised hosts and
difficulty in medical management of these infections, preven-
tion of their occurrence can be expected to have a significant
impact on overall patient morbidity and mortality and related
health care expenditures (1, 4, 5, 16). The emergence of resis-
tance among fungal pathogens, either appearing de novo or
through selection of species with intrinsic resistance mecha-
nisms (e.g., fluconazole resistance in Candida krusei), further
confounds this problem and poses special challenges in patient
management (3, 11).
Prevention of local catheter site infections by both bacterial
and fungal pathogens is an important component in controlling
nosocomial bloodstream infections and improving patient out-
comes (15, 19). Efforts to decrease infection rates have in-
cluded education on proper catheter insertion techniques and
care, use of sterile barrier precautions, and appropriate skin
decontamination given many such infections follow from inva-
sion of the transcutaneous catheter tract (15). The usual skin
decontamination protocols have utilized povidone-iodine, iso-
propyl alcohol, and/or chlorhexidine gluconate, including the
use of a chlorhexidine-impregnated dressing (7). The recent
description of human antimicrobial peptides such as defensins
and cathelicidins as possible effector molecules in prevention
of infection is another novel therapeutic approach based upon
the antimicrobial properties of naturally occurring compounds
found in leukocytes and epithelial secretions of vertebrates (8).
One such agent is omiganan, a rapidly bactericidal and fungi-
cidal cationic peptide analog of indolicidin that is known to
significantly reduce normal skin flora counts following topical
applications (18). This agent is being developed as a topical
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TABLE 1. Cumulative percent inhibited at omiganan MICs tested against six groups of yeasts and molds (126 isolates)
Organism group
(no. of isolates tested)
Cumulative % organisms inhibited at MIC (g/ml) ofa:
0.5 1 2 4 8 16 32 64 128 256 512 1,024
Candida spp. (106) 0 0 0 0 0 4 14 51 81 100
C. albicans (52) 0 0 0 0 0 0 2 65 100
C. glabrata (22) 0 0 0 0 0 0 0 0 18 100
C. krusei (10) 0 0 0 0 0 0 20 70 100
C. parapsilosis (11) 0 0 0 0 0 0 9 18 82 100
C. tropicalis (11) 0 0 0 0 0 36 100
Molds (20) 0 5 5 5 15 20 25 45 60 80 80 100
Aspergillus spp. (10) 0 0 0 0 0 10 20 30 50 60 60 100
Non-Aspergillus (10)b 9 10 10 10 30 30 30 60 70 100
a Omiganan clinical formulation concentration  10,000 g/ml.
b Curvularia spp. (2 isolates), Fusarium spp. (2 isolates), Paecilomyces variotii (1 isolate), Penicillium marneffei (1 isolate), and Penicillium spp. (4 isolates).
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antimicrobial agent and is currently in a phase III U.S. and
European clinical trial for prevention of catheter-associated
infections and in preclinical development for other indications
(8–10, 17, 18).
The purpose of this study was to update and expand the
analysis of omiganan activity against prevalent fungal patho-
gens, to better characterize the compound’s breadth of spec-
trum and potency against species commonly encountered in
catheter colonization and catheter-associated bloodstream in-
fections, and also to establish the level of activity against prev-
alent mold species. (This material was presented in part at the
47th Annual Meeting of the Interscience Conference on An-
timicrobial Agents and Chemotherapy held in Chicago, IL, 11
to 20 September 2007.)
Test organisms originated from sterile site infections (126
isolates; bloodstream, respiratory tract, and deep tissues recov-
ered during 2005 and 2006) and included Candida albicans (52
isolates), Candida glabrata (22 isolates), Candida tropicalis (11
isolates), Candida parapsilosis (11 isolates), C. krusei (10 iso-
lates), Aspergillus spp. (10 isolates), and other mold species (10
isolates).
Broth microdilution MIC testing was performed according
to CLSI methods (documents M27-A2, M27-S2, and M38-A;
2002) (6, 12, 13). Omiganan standard powder was solubilized
in sterile distilled water; other agents were handled as recom-
mended by CLSI (12, 13). Panels were produced by JMI Lab-
oratories (North Liberty, IA) using RPMI-1640 broth supple-
mented with morpholinepropanesulfonic acid buffer; results
were recorded at 48 h as specified, and interpretive criteria,
where available, were those published in M27-S2 (12). Quality
control (QC) was performed as recommended in M27-A2 and
M38-A (12, 13) using the following QC strains: C. parapsilosis
ATCC 22019 and C. krusei ATCC 6258. Omiganan QC ranges
utilized were those of Anderegg et al. (2), and all QC results
for omiganan and comparator antifungal agents were within
the specified control ranges.
Omiganan inhibited all Candida sp. isolates within a 4-log2
dilution range (16 to 256 g/ml), being most active against C.
tropicalis, C. albicans, and C. krusei (concentration at which 50%
or 90% of organisms are inhibited [MIC50/MIC90], 32 to 64/32 to
128 g/ml) and least active against C. glabrata and C. parapsilosis
(MIC50/MIC90, 128 to 256/256 g/ml [Table 1]). Similar antifun-
gal activity (MIC50, 64 g/ml) was evident against C. krusei with
intrinsic resistance to fluconazole (MIC50, 32 g/ml) compared
with that of C. albicans (MIC50, 1 g/ml [Table 2]). While all
mold isolates were inhibited by 1,024 g/ml of omiganan,
MIC90s for non-Aspergillus spp. were generally fourfold lower
than those for Aspergillus spp. (Tables 1 and 2).
Among comparator antifungal agents, results were highly
variable and species dependent, with C. krusei being the most
resistant to all agents except voriconazole (Table 2). Only
amphotericin B and omiganan (MIC90, 1 to 2 and 32 to 256
g/ml, respectively) displayed consistent activity against all
yeast and mold species.
In the current clinical gel formulation of 1% gel (topical
concentration, 10,000 g/ml), omiganan was active against all
commonly isolated yeast and mold pathogens (highest docu-
mented MICs, 256 and 1,024 g/ml, respectively) associated
with catheter-related or sterile site infection, including those
species with intrinsically reduced susceptibilities to other anti-
fungal agents (Table 2).
This cationic peptide (omiganan) represents a “first-in-
class” topical agent that displays broad antifungal and antibac-
terial coverage of all major pathogens responsible for local
catheter site and catheter-associated bloodstream infections;
none of the currently marketed topical antimicrobials (mupiro-
TABLE 2. Activities of omiganan and comparator antifungal agents









Omiganan 64 128 32–128 —/—
Amphotericin B 1 1 0.5–1 —/—
Fluconazole 1 64 0.12–64 67.3/30.8
5-Flucytosine 0.12 1 0.03–2 100.0/0.0
Itraconazole 0.12 16 0.008–16 50.0/48.1
Nystatin 8 8 8 —/—
Voriconazole 0.03 16 0.008–16 75.0/25.0
Candida glabrata (22)
Omiganan 256 256 128–256 —/—
Amphotericin B 1 1 0.5–1 —/—
Fluconazole 4 64 1–64 77.3/18.2
5-Flucytosine 0.06 0.06 0.03–0.06 100.0/0.0
Itraconazole 0.12 0.5 0.03–1 72.7/4.6
Nystatin 8 8 8 —/—
Voriconazole 0.06 2 0.03–2 86.4/0.0
Candida krusei (10)
Omiganan 64 128 32–128 —/—
Amphotericin B 1 2 0.5–2 —/—
Fluconazole 32 64 32–64 0.0/100.0
5-Flucytosine 16 32 8–32 0.0/30.0
Itraconazole 0.5 0.5 0.12–0.5 10.0/0.0
Nystatin 8 8 8 —/—
Voriconazole 0.25 0.5 0.12–0.5 100.0/0.0
Candida parapsilosis (11)
Omiganan 128 256 32–256 —/—
Amphotericin B 1 1 1 —/—
Fluconazole 0.5 16 0.5–16 81.8/0.0
5-Flucytosine 0.12 0.12 0.06–0.12 100.0/0.0
Itraconazole 0.06 0.25 0.015–0.25 63.6/0.0
Nystatin 8 8 8 —/—
Voriconazole 0.015 0.12 0.008–0.12 100.0/0.0
Candida tropicalis (11)
Omiganan 32 32 16–32 —/—
Amphotericin B 1 1 0.5–1 —/—
Fluconazole 0.25 64 0.12–64 81.8/18.2
5-Flucytosine 0.06 0.12 0.06–0.12 100.0/0.0
Itraconazole 0.03 0.12 0.015–0.12 100.0/0.0
Nystatin 8 8 8 —/—
Voriconazole 0.015 16 0.015–16 72.7/27.3
Aspergillus spp. (10)
Omiganan 128 1024 16–1024 —/—
Amphotericin B 0.5 1 0.12–1 —/—
Fluconazole 64 64 32–64 —/—
5-Flucytosine 64 64 1–64 —/—
Itraconazole 0.03 0.06 0.008–0.12 —/—
Nystatin 16 16 2–32 —/—
Voriconazole 0.25 0.25 0.06–0.25 —/—
Non-Aspergillus sp.
molds (10)
Omiganan 64 256 1–256 —/—
Amphotericin B 0.25 0.5 0.015–1 —/—
Fluconazole 64 64 1–64 —/—
5-Flucytosine 64 64 0.25–64 —/—
Itraconazole 0.06 16 0.008–16 —/—
Nystatin 8 16 0.5–16 —/—
Voriconazole 0.25 2 0.008–16 —/—
a Criteria as published by the CLSI (2005); —, no breakpoint available.
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cin, triple antibiotic ointment, or retapamulin) demonstrates a
spectrum that has comparable breadth. Given the availability
of standardized antifungal susceptibility test methods (12, 13),
ongoing surveillance of fungal pathogens implicated in cathe-
ter-associated infections will be an important management tool
to anticipate changes in species composition, infection rates,
and trends of resistance to the applied topical agents, including
omiganan.
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